LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience.

    Pérez Ramírez, S / Del Monte-Millán, M / López-Tarruella, S / Martínez Jáñez, N / Márquez-Rodas, I / Lobo Samper, F / Izarzugaza Perón, Y / Rubio Terres, C / Rubio Rodríguez, D / García-Sáenz, J Á / Moreno Antón, F / Zamora Auñón, P / Arroyo Yustos, M / Lara Álvarez, M Á / Ciruelos Gil, E M / Manso Sánchez, L / Echarri González, M J / Guerra Martínez, J A / Jara Sánchez, C /
    Bueno Muiño, C / García Adrián, S / Carrión Galindo, J R / Valentín Maganto, V / Martín, M

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

    2019  Volume 22, Issue 5, Page(s) 717–724

    Abstract: Introduction: The aim of this study is to evaluate the cost-effectiveness and impact of gene-expression assays (GEAs) on treatment decisions in a real-world setting of early-stage breast cancer (ESBC) patients.: Methods: This is a regional, ... ...

    Abstract Introduction: The aim of this study is to evaluate the cost-effectiveness and impact of gene-expression assays (GEAs) on treatment decisions in a real-world setting of early-stage breast cancer (ESBC) patients.
    Methods: This is a regional, prospective study promoted by the Council Health Authorities in Madrid. Enrolment was offered to women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, node-negative or micrometastatic, stage I or II breast cancer from 21 hospitals in Madrid. Treatment recommendations were recorded before and after knowledge of tests results. An economic model compared the cost-effectiveness of treatment, guided by GEAs or by common prognostic factors.
    Results: 907 tests (440 Oncotype DX
    Conclusion: Using GEAs to guide adjuvant therapy in ESBC is cost-effective in Spain and has a significant impact on treatment decisions.
    MeSH term(s) Adolescent ; Adult ; Aged ; Biomarkers, Tumor/genetics ; Breast Neoplasms/drug therapy ; Breast Neoplasms/economics ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Chemotherapy, Adjuvant ; Clinical Decision-Making ; Cost-Benefit Analysis ; Female ; Gene Expression Profiling/economics ; Gene Expression Profiling/methods ; Humans ; Middle Aged ; Prospective Studies ; Quality-Adjusted Life Years ; Registries ; Spain/epidemiology ; Young Adult
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2019-07-12
    Publishing country Italy
    Document type Journal Article ; Multicenter Study
    ZDB-ID 2397359-6
    ISSN 1699-3055 ; 1699-048X
    ISSN (online) 1699-3055
    ISSN 1699-048X
    DOI 10.1007/s12094-019-02176-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6644: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Update on adjuvant hormonal treatment of early breast cancer.

    Lao Romera, J / Puertolas Hernández, T J / Peláez Fernández, I / Sampedro Gimeno, T / Fernández Martínez, R / Fernández Pérez, I / Iranzo González Cruz, V / Illarramendi Mañas, J J / Garcerá Juan, S / Ciruelos Gil, E M

    Advances in therapy

    2011  Volume 28 Suppl 6, Page(s) 1–18

    Abstract: Clinical trials conducted over the last two decades have demonstrated that 5 years of treatment with tamoxifen (TAM) after local treatment in postmenopausal patients with positive hormone receptor early breast cancer improves disease-free survival and ... ...

    Abstract Clinical trials conducted over the last two decades have demonstrated that 5 years of treatment with tamoxifen (TAM) after local treatment in postmenopausal patients with positive hormone receptor early breast cancer improves disease-free survival and overall survival. More recently, aromatase inhibitors (AI) have been tested in several randomized clinical trials in this setting. The studies have tested either AI versus TAM or different sequential approaches combining the two agents. While the most effective strategy remains to be determined, overall, incorporation of AI resulted in better disease-free survival, particularly in the worst-prognosis subgroup of patients. In addition, long-term treatment with AI was, in general, well tolerated. However, mature results are needed in order to be able to assess the effect in overall survival. The authors of this supplement paper include the key points of roundtable presentations and discussions of hormonal therapy in breast cancer by topic.
    MeSH term(s) Administration, Oral ; Adult ; Aged ; Antineoplastic Agents, Hormonal/administration & dosage ; Antineoplastic Agents, Hormonal/adverse effects ; Aromatase Inhibitors/administration & dosage ; Aromatase Inhibitors/adverse effects ; Breast Neoplasms/drug therapy ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Breast Neoplasms/surgery ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Humans ; Mastectomy/methods ; Middle Aged ; Neoplasm Staging ; Nitriles/administration & dosage ; Nitriles/adverse effects ; Randomized Controlled Trials as Topic ; Risk Assessment ; Survival Analysis ; Tamoxifen/administration & dosage ; Tamoxifen/adverse effects ; Time Factors ; Treatment Outcome ; Triazoles/administration & dosage ; Triazoles/adverse effects
    Chemical Substances Antineoplastic Agents, Hormonal ; Aromatase Inhibitors ; Nitriles ; Triazoles ; Tamoxifen (094ZI81Y45) ; anastrozole (2Z07MYW1AZ)
    Language English
    Publishing date 2011-09
    Publishing country United States
    Document type Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 632651-1
    ISSN 1865-8652 ; 0741-238X
    ISSN (online) 1865-8652
    ISSN 0741-238X
    DOI 10.1007/s12325-011-0017-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2101: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top